FDA Approves OCREVUS ZUNOVO — Genentech, Inc.

Genentech, Inc. received FDA clearance for OCREVUS ZUNOVO, a once-monthly subcutaneous formulation of Ocrelizumab combined with recombinant Hyaluronidase. The approval is projected to drive increased market share for the multiple sclerosis therapy by significantly improving patient adherence and convenience compared to the standard intravenous infusion.